South Australian Meningococcal B Vaccine Herd Immunity Study in Adolescents
A cluster randomised controlled trial to assess the impact of meningococcal B vaccine 4CMenB on nasopharyngeal carriage of N. Meningitidis in adolescents in South Australia
The University of Adelaide
44,000 participants
Apr 3, 2017
Interventional
Conditions
Summary
To estimate the effect on carriage, all year 10, 11, and 12 students will be offered 4CMenB vaccination in South Australia through schools over the study period with 50% of the students enrolled receiving the vaccine in 2017 and 50% in 2018. In year 10 and 11 students, posterior pharyngeal swabs will be obtained at baseline and 12 months post baseline to estimate the difference in carriage prevalence of all genogroups of N. meningitidis between vaccinated and unvaccinated participants.
Eligibility
Inclusion Criteria4
- South Australian secondary school students in years 10, 11, and 12 in 2017
- Written parental consent for those under the age of 18
- Written student consent-assent for those under the age of 18 (or if 18 years old and older consent for themselves)
- Available at school for at least the first pharyngeal swab
Exclusion Criteria3
- Previous recipient of 4CMenB vaccine (Bexsero)
- Known pregnancy
- Anaphylaxis following any component of the 4CMenB vaccine
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Group A - 2017 Students within schools randomised to group A will receive two doses of 0.5ml of the licensed 4CMenB vaccine administered by intramuscular injection in 2017, with an interval of 1-2 months between doses, as per the Australian Technical Advisory Group on Immunisation recommendations. An oropharyngeal swab will be collected at baseline and at 12 months. Group B - 2018 Students within schools randomised to group B will receive two doses of 0.5ml of the licensed 4CMenB vaccine administered by intramuscular injection in 2018, with an interval of 1-2 months between doses. Following completion of baseline and 12 month oropharyngeal swab.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12617000079347